Abstract: The present application relates to substituted dyes containing bis-boron fused heterocycles and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

Abstract: The present invention describes a method which outlines a process for conversion of CBD to a ?9-tetrahydrocannabinol (?9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the ?9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% ?9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce ?9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% ?9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the ?9-THC using distillation and collecting an essentially pure fraction of ?9-THC using additional distillation or enrichment form of purification.

Abstract: Provided, in part, are compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with the activity of sodium channels. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The disclosure provides processes for synthesizing compounds for use as CFTR modulators.

Abstract: Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and/or anxiety disorder, each individually or concurrent.

Abstract: A method for producing a fatty acid-cannabinoid-plasma protein (FCP) composition, the method comprising: contacting a plasma protein or a peptide portion thereof with a supplemental fatty acid composition comprising at least one fatty acid; and contacting the plasma protein or portion thereof with a cannabinoid composition comprising at least one cannabinoid, such that a combined composition is prepared, which comprises a FCP complex in which the at least one fatty acid and the at least one cannabinoid is bound to the plasma protein or portion thereof.

Abstract: Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.

Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.

Abstract: The invention features methods of treating cancer with ?-GPA. The disclosure also provides methods of treating cancer including combinations of ?-GPA and additional anti-cancer therapies.

Abstract: Novel pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Abstract: Emmacin-related substituted dihydropyrimidine compounds demonstrate potency at low concentrations and inhibit Methicillin-resistant S. aureus growth.

Abstract: Crystalline forms of a C-C chemokine receptor type 4 (CCR4) antagonist, oral dosage forms of same and methods of using and preparing same, are provided.

Abstract: Compositions, methods, and kits are provided for treating bacterial infections with nanoparticles comprising a thiol-binding metallic core conjugated to a fluoroquinolone antibiotic. Recalcitrant infections are often difficult to treat because of the presence of persister cells, a subpopulation of bacterial cells that is highly tolerant of traditional antibiotics. Persister cells are dormant, which makes them less susceptible to many antibiotics, which are designed to kill growing cells. Administration of nanoparticles comprising a thiol-binding metallic core conjugated to fluoroquinolone antibiotics was found to be highly efficacious in eradicating persister cells and for treating infections for a broad range of bacterial species, including Gram-positive and Gram-negative bacteria. Such treatment was effective not only in eradicating planktonic bacteria but also bacteria in biofilms.

Abstract: A N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present invention relates to a method for producing a high yield of an organometallic compound including a step of allowing a metal hexacarbonyl compound to react with a hexahydro-1,3,5-triazine compound, and a thin film having excellent properties, fabricated by depositing the produced organometallic compound.

Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Abstract: The present disclosure belongs to the technical field of tissue regeneration, and specifically relates to use of tacrolimus in preparation of a medicament for initiating a tissue regeneration function. In the present disclosure, adding the tacrolimus may initiate the tissue regeneration of a non-regenerative distal caudal fin in a caudal fin resection experiment of a zebrafish. The present disclosure finds that tacrolimus inhibits the calcineurin activity and has a novel use for initiating the tissue regeneration of non-regenerative tissues. The present disclosure expands the use field of tacrolimus and has important value.

Abstract: Novel imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Abstract: Disclosed are new polycyclic carbogenic molecules and their methods of synthesis. The new polycyclic carbogenic molecules may be utilized in anti-cancer therapies. In particular, the polycyclic carbogenic molecules may be formulated as pharmaceutical compositions that comprise the small molecules, which compositions may be administered in methods of treating and/or preventing cell proliferative diseases and disorders such as cancer. The new polycyclic carbogenic molecules may be prepared from vinyl- or allyl-substituted cyclohexenone precursors via preparation of a silyl bis-enol ether intermediate.

Abstract: The present invention is directed to a personal composition comprising a) a strobilurin; b) a 2-pyridinol-N-oxide material wherein the ratio of a:b is from about 10:1 to about 1:20; wherein there is a synergistic anti-inflammatory/cellular stress activity.